BIOMAT Database Logo BIOMAT Database Logo

Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer. 2004

K Goto, and I Sekine, and Y Nishiwaki, and R Kakinuma, and K Kubota, and T Matsumoto, and H Ohmatsu, and S Niho, and T Kodama, and T Shinkai, and T Tamura, and Y Ohe, and H Kunitoh, and N Yamamoto, and H Nokihara, and K Yoshida, and T Sugiura, and K Matsui, and N Saijo
Division of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan. kgoto@east.ncc.go.jp

Irinotecan (CPT-11) has been shown to exhibit excellent antitumour activity against small-cell lung cancer (SCLC). A multi-institutional phase II study was therefore conducted to evaluate the efficacy and toxicity of CPT-11 combined with cisplatin (CDDP) and etoposide (ETOP) (PEI regimen) for the treatment of sensitive relapsed SCLC. Patients who responded to first-line chemotherapy but relapsed more than 8 weeks after the completion of first-line therapy (n=40) were treated using the PEI regimen, which consisted of CDDP (25 mg m(-2)) weekly for 9 weeks, ETOP (60 mg m(-2)) for 3 days on weeks 1, 3, 5, 7, and 9, and CPT-11 (90 mg m(-2)) on weeks 2, 4, 6, and 8 with granulocyte colony-stimulating factor support. Five complete responses and 26 partial responses were observed, and the overall response rate was 78% (95% confidence interval 61.5-89.2%). The median survival time was 11.8 months, and the estimated 1-year survival rate was 49%. Grade 3/4 leucocytopenia, neutropenia, and thrombocytopenia were observed in 55, 73, and 33% of the patients, respectively. Nonhaematological toxicities were mild and transient in all patients. In conclusion, the PEI regimen is considered to be highly active and well tolerated for the treatment of sensitive relapsed SCLC.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D009503 Neutropenia A decrease in the number of NEUTROPHILS found in the blood. Neutropenias
D002166 Camptothecin An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity. Camptothecine
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

K Goto, and I Sekine, and Y Nishiwaki, and R Kakinuma, and K Kubota, and T Matsumoto, and H Ohmatsu, and S Niho, and T Kodama, and T Shinkai, and T Tamura, and Y Ohe, and H Kunitoh, and N Yamamoto, and H Nokihara, and K Yoshida, and T Sugiura, and K Matsui, and N Saijo
Cisplatin, Etoposide, and Irinotecan for Relapsed Small-Cell Lung Cancer.
November 2016, Translational cancer research,
K Goto, and I Sekine, and Y Nishiwaki, and R Kakinuma, and K Kubota, and T Matsumoto, and H Ohmatsu, and S Niho, and T Kodama, and T Shinkai, and T Tamura, and Y Ohe, and H Kunitoh, and N Yamamoto, and H Nokihara, and K Yoshida, and T Sugiura, and K Matsui, and N Saijo
Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer.
December 2007, International journal of cancer,
K Goto, and I Sekine, and Y Nishiwaki, and R Kakinuma, and K Kubota, and T Matsumoto, and H Ohmatsu, and S Niho, and T Kodama, and T Shinkai, and T Tamura, and Y Ohe, and H Kunitoh, and N Yamamoto, and H Nokihara, and K Yoshida, and T Sugiura, and K Matsui, and N Saijo
Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer.
March 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
K Goto, and I Sekine, and Y Nishiwaki, and R Kakinuma, and K Kubota, and T Matsumoto, and H Ohmatsu, and S Niho, and T Kodama, and T Shinkai, and T Tamura, and Y Ohe, and H Kunitoh, and N Yamamoto, and H Nokihara, and K Yoshida, and T Sugiura, and K Matsui, and N Saijo
Multi-institutional phase I/II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung carcinoma.
March 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
K Goto, and I Sekine, and Y Nishiwaki, and R Kakinuma, and K Kubota, and T Matsumoto, and H Ohmatsu, and S Niho, and T Kodama, and T Shinkai, and T Tamura, and Y Ohe, and H Kunitoh, and N Yamamoto, and H Nokihara, and K Yoshida, and T Sugiura, and K Matsui, and N Saijo
E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer.
January 2014, Cancer chemotherapy and pharmacology,
K Goto, and I Sekine, and Y Nishiwaki, and R Kakinuma, and K Kubota, and T Matsumoto, and H Ohmatsu, and S Niho, and T Kodama, and T Shinkai, and T Tamura, and Y Ohe, and H Kunitoh, and N Yamamoto, and H Nokihara, and K Yoshida, and T Sugiura, and K Matsui, and N Saijo
Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer.
September 2005, Clinical lung cancer,
K Goto, and I Sekine, and Y Nishiwaki, and R Kakinuma, and K Kubota, and T Matsumoto, and H Ohmatsu, and S Niho, and T Kodama, and T Shinkai, and T Tamura, and Y Ohe, and H Kunitoh, and N Yamamoto, and H Nokihara, and K Yoshida, and T Sugiura, and K Matsui, and N Saijo
Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.
March 2017, Clinical lung cancer,
K Goto, and I Sekine, and Y Nishiwaki, and R Kakinuma, and K Kubota, and T Matsumoto, and H Ohmatsu, and S Niho, and T Kodama, and T Shinkai, and T Tamura, and Y Ohe, and H Kunitoh, and N Yamamoto, and H Nokihara, and K Yoshida, and T Sugiura, and K Matsui, and N Saijo
Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer.
March 2006, Clinical lung cancer,
K Goto, and I Sekine, and Y Nishiwaki, and R Kakinuma, and K Kubota, and T Matsumoto, and H Ohmatsu, and S Niho, and T Kodama, and T Shinkai, and T Tamura, and Y Ohe, and H Kunitoh, and N Yamamoto, and H Nokihara, and K Yoshida, and T Sugiura, and K Matsui, and N Saijo
Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer.
February 2008, British journal of cancer,
K Goto, and I Sekine, and Y Nishiwaki, and R Kakinuma, and K Kubota, and T Matsumoto, and H Ohmatsu, and S Niho, and T Kodama, and T Shinkai, and T Tamura, and Y Ohe, and H Kunitoh, and N Yamamoto, and H Nokihara, and K Yoshida, and T Sugiura, and K Matsui, and N Saijo
Carboplatin plus etoposide for sensitive relapsed small-cell lung cancer.
December 2020, The Lancet. Oncology,
Copied contents to your clipboard!